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Glioblastoma (GBM) is the most aggressive adult glioma with a median survival of 14
months. While standard treatments (safe maximal resection, radiation, and temozolomide
chemotherapy) have increased the median survival in favorable O(6)-methylguanine-DNA
methyltransferase (MGMT)-methylated GBM (∼21months), a large proportion of patients
experience a highly debilitating and rapidly fatal disease. This study examined GBM
cellular energetic pathways and blockade using repurposed drugs: the glycolytic inhibitor,
namely dicholoroacetate (DCA), and the partial fatty acid oxidation (FAO) inhibitor, namely
ranolazine (Rano). Gene expression data show that GBM subtypes have similar glucose
and FAO pathways, and GBM tumors have significant upregulation of enzymes in
both pathways, compared to normal brain tissue (p < 0.01). DCA and the DCA/Rano
combination showed reduced colony-forming activity of GBM and increased oxidative
stress, DNA damage, autophagy, and apoptosis in vitro. In the orthotopic Gl261 and
CT2A syngeneic murine models of GBM, DCA, Rano, and DCA/Rano increased median
survival and induced focal tumor necrosis and hemorrhage. In conclusion, dual targeting
of glycolytic and FAO metabolic pathways provides a viable treatment that warrants
further investigation concurrently or as an adjuvant to standard chemoradiation for GBM.
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INTRODUCTION
Glioblastoma (GBM) is a biologically heterogeneous and uniformly fatal disease. Verhaak et al.
(1) describe classical, mesenchymal, neural, and proneural subtypes of GBM based on an 840
gene signature. These have been adopted as clinically relevant molecular subtypes with different
disease progression and prognosis. While brain cancer makes up 1.3% of all new cancer diagnoses
in Australia, it accounts for 3.2% of cancer-related deaths (2). GBM accounts for 54% of brain
cancer cases and has a 5-year survival rate <5% (3). Despite the recognized heterogeneity in
GBM epigenetics, genetics, and transcription (4); histological patterns (5); immune infiltration
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(6); and metabolism (7), the current treatment for GBM
remains maximal safe surgical resection, followed by external
beam radiation therapy (RT) with concurrent and adjuvant
temozolomide (TMZ) (8). This increases median overall survival
from 14 months for TMZ-resistant O(6)-methylguanine-DNA
methyltransferase (MGMT) promoter unmethylated GBMs to
21.2 months for TMZ-sensitive MGMT promoter methylated
GBMs (9).
In addition to a uniform reliance of cancer cells on aerobic
glycolysis, recent studies have demonstrated the dependence
of GBM cells on fatty acid oxidation (FAO) (7). Human
gliomas express the FAO enzymes medium-chain acyl-CoA
dehydrogenase (MCAD), short-chain L-3-hydroxyacyl-
CoA dehydrogenase (SCHAD), very-long-chain acyl-CoA
dehydrogenase (VLCAD), hydroxyacyl-CoA dehydrogenase
(HADH)/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase
(ECH), and carnitine palmitoyltransferase 1a (CPT1a)
and demonstrate decreased oxygen consumption in the
presence of an FAO inhibitor, etomoxir (10). Genomic,
metabolomic, and functional analyses by Prabhu et al. (7)
show that FAO is a key driver of progression from low-
grade gliomas into GBM. In a syngeneic glioma model
(oncogenic neural stem cells), etomoxir increased survival
(10), whereas, the combination of etomoxir, glucose analog,
and glycolytic inhibitor 2-deoxy-D-glucose (2-DG) led to
metabolic lethality in vitro and increased median survival
in MES93 mesenchymal GBM tumor-bearing mice (11).
Ranolazine (Rano), a partial FAO inhibitor, has shown
neuroprotective effects on healthy astrocytes and neurons
in rodent cell cultures (12). Targeting FAO in GBM also
shows promise in alleviating the immunosuppressive tumor
microenvironment as FAO ameliorates the tolerogenic and
immunosuppressive mechanisms of tumor myeloid-derived
suppressor cells (MDSC) and reduces tumor growth in the
syngeneic murine models of lung (3LL) and colon (MCA-38)
cancer (13).
Glycolytic inhibitor dichloroacetate (DCA) induces apoptosis
in GBM and putative GBM stem cells in vitro and in vivo
(14) and has demonstrated clinical efficacy in a small cohort
of patients with GBM (15). In addition, DCA sensitizes
GBM to radiation (16) and has synergistic effects on GBM
growth and survival induced by mitochondrial oxidative
stress, when combined with mitochondrial inhibitor 4-[N-
(S-penicillaminylacetyl)amino] phenylarsonous acid (17) and
when inhibiting stem cell self-renewal in combination with
metformin (18).
Glucose metabolism and reactive oxygen species (ROS)
are bidirectionally linked, and cancer cells are metabolically
adaptive to the changing oxygen and nutrient microenvironment
(19). Therein, it was hypothesized that dual blockade of the
glycolysis and FAO pathways would inhibit GBM tumor
growth by increasing oxidative phosphorylation and enhancing
chemoradiation-induced ROS. In the present study, we
investigative the novel combination of the glycolytic inhibitor,
DCA, and the partial FAO inhibitor, Rano, in two syngeneic
immune-competent models of GBM, against “standard of care”
chemoradiation.
MATERIALS AND METHODS
Human Gene Expression Data
Gene lists for human glucose (#RAH49R3) and FAOmetabolism
(#RPKA3DE) were obtained from Taqman R© Arrays (https://
www.thermofisher.com). Gene expression and GBM subtype
data from 48 primary GBM cell lines were acquired from the
human glioblastoma cell culture (HGCC) Affymetrix Human
Exon 1.0 ST Array (NCBI Gene Omnibus GSE72217; https://
www.ncbi.nlm.nih.gov/geo/) (20). Classical, mesenchymal,
proneural, and neural GBM subtyping was performed by HGCC
(20) using the gene signatures described by Verhaak et al.
(1). Data were analyzed using Gene Cluster 3.0 for Windows,
Department of Genetics, Stanford University, CA, USA (21)
and TreeView 3.0 beta1 for Windows, Department of Genetics,
Stanford University, CA, USA (22) with the Pearson’s correlation
proximity-based hierarchical clustering. The Cancer Genome
Atlas (TCGA; https://www.cancer.gov/tcga) GBM, TCGA
normal, and the Genotype-Tissue Expression (GTEx; https://
www.gtexportal.org/home/) data box plots were acquired
through the Gene Expression Profiling Interactive Analysis
(23) (GEPIA; available at http://gepia.cancer-pku.cn/). Data
are expressed as the log2 fold change (FC) [defined as median
(tumor) – median (normal)].
Cells
Murine glioma Gl261 cells were donated by Géza Safrany
(Frederic Joliot-Curie National Research Institute for Radiology
and Radiohygiene, Budapest, Hungary) and CT2A by Tomas
Seyfried (Boston College, Boston, MA, USA). U-87MG, U-
251MG, and T98G from the CellBank Australia, Westmead,
NSW, Australia. Cell lines were authenticated by the Satellite
Tandem Repeat profiling (Garvan Institute of Medical Research,
Sydney, NSW, Australia) and mycoplasma negative by the
MycoProbe R© Mycoplasma Detection Kit (R&D Systems, Inc.,
Minneapolis, MN, USA). Cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% v/v fetal
bovine serum (FBS) in a humidified incubator with 5% CO2 at
37◦C with 60% relative humidity.
Treatments
Drugs used in this study were DCA (sodium DCA #347795;
Sigma-Aldrich, St. Louis, MO, USA), TMZ (#T2577; Sigma-
Aldrich St. Louis, MO, USA), and Rano (Rano dihydrochloride
#R6152; Sigma-Aldrich St. Louis, MO, USA) dissolved in
complete media for in vitro studies and in sterile water for in
vivo studies at stock concentrations of 40, 5, and 10 mg/ml,
respectively. X-ray radiation was delivered using the Small
Animal Radiation Research Platform (SARRP; Xstrahl Inc.,
Suwanee, GA, USA) at a dose rate of 2.97 Gy/min as described
earlier (24). In all experiments, the drug treatment preceded
irradiation by 1 h to enable the drugs to act on their respective
cellular targets. The cells were detached with 0.5% v/v and
trypsin/0.2% v/v ethylenediaminetetraacetic acid in phosphate-
buffered saline (PBS) and counted by MUSE R© cell count and
viability assay (Luminex Corp., Austin, TX, USA) according to
the instructions of the manufacturer.
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FIGURE 1 | Human gene expression of glucose and fatty acid oxidation (FAO) pathways. (A) Heat map and hierarchical clustering of genes associated with the
glucose and FAO metabolic pathways. (B) Human glioblastoma cell culture (HGCC) glioblastoma (GBM) subtype gene expression of selected targetable enzymes
involved in glycolytic and β-oxidation pathways. (C) The Cancer Genome Atlas (TCGA) GBM vs. normal gene expression. Data are expressed as median ±
interquartile range of log2 fold change [median (tumor) − median (normal)]. *p < 0.01 by the Kruskal–Wallis test with the Dunn’s multiple comparison test.
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FIGURE 2 | Sensitivity and survival of murine glioma cell lines to drug and radiation therapy (RT) treatment combinations. (A) Drug IC50s for temozolomide (TMZ),
dicholoroacetate (DCA), and ranolazine (Rano) were determined from confluency at 72 h and for RT by clonogenic assay at 10 days post-treatment using a
four-parameter logistic model. Symbols show mean survival (%) ± SEM for six replicates per experiment (N = 3). (B) Heat maps of the cell survival for TMZ/RT and
DCA/Rano combinations. Black boxes represent the best synergy combination indices as calculated using the CompuSyn Software (Paramus, NJ, USA).
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FIGURE 3 | Temozolomide (TMZ), RT, DCA, and their combination reduce GBM cell proliferation. (A) Percentage effect of dual-read time-resolved fluorescent lifetime
at 60-min post-treatment relative to untreated control (Unt) for fatty acid oxidation (FAO) and glycolytic and oxidative phosphorylation (OxPhos) metabolism. Carbonyl
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP; 2.5µm), etomoxir (Eto; 40µm), and antimycin A (AA; 1µm) were used as positive and negative controls where
appropriate. Data are expressed as mean of triplicates. (B) Micrographs of colonies (>50 cells) 10-day post-treatment. (C) Column graphs show mean ± SEM of
triplicates from three independent experiments. Column graphs show the mean ± SEM from three independent experiments ap < 0.05 vs. Unt; bp < 0.05 vs. TMZ; cp
< 0.05 vs. RT; dp < 0.05 vs. DCA; ep < 0.05 vs. ranolazine (Rano); fp < 0.05 vs. TMZ/RT; gp < 0.05 vs. DCA/Rano; and hp < 0.05 vs. All-combined treatments were
determined by Kruskal–Wallis test alongwith the Dunn’s multiple comparison test.
Frontiers in Oncology | www.frontiersin.org 5 March 2021 | Volume 11 | Article 633210
McKelvey et al. Metabolic Blockade Improves GBM Survival
FIGURE 4 | DCA/ranolazine (Rano) increases reactive oxygen species (ROS) levels in murine GBM cells. (A) Representative Luminex® histograms (Luminex Corp.,
Austin, TX, USA) show the ROS fluorescent intensity as ROS− (M1; blue) and ROS+ (M2; red) in Gl261 and CT2A GBM lines. (B) Column graphs showing the mean ±
SEM from three independent experiments as in (A). ap < 0.05 vs. Unt; bp < 0.05 vs. temozolomide (TMZ); cp < 0.05 vs. radiation therapy (RT); dp < 0.05 vs. DCA; ep
< 0.05 vs. Rano; fp < 0.05 vs. TMZ/RT; and gp < 0.05 vs. All-combined treatments were determined by the two-way ANOVA test along with the Tukey’s multiple
comparison test.
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FIGURE 5 | TMZ and DCA increase DNA damage in GBM cell lines. (A) Representative Luminex® dot plots (Luminex Corp., Austin, TX, USA) depict increased
phosphoryated ataxia telangiectasia mutated (ATM) (upper left), phosphoryated H2A.X (lower right), or both (DSB; upper right). (B) Column graphs show mean ± SEM
from three independent experiments as in (A). ap < 0.05 vs. Unt; bp < 0.05 vs. TMZ; cp < 0.05 vs. RT; dp < 0.05 vs. DCA; ep < 0.05 vs. Rano; fp < 0.05 vs.
(Continued)
Frontiers in Oncology | www.frontiersin.org 7 March 2021 | Volume 11 | Article 633210
McKelvey et al. Metabolic Blockade Improves GBM Survival
FIGURE 5 | TMZ/RT; gp < 0.05 vs. DCA/Rano; and hp < 0.05 vs. All-combined treatments were determined by the two-way ANOVA test along with the Tukey’s
multiple comparison test. (C) Western blot immunoblot (top) and densitometric analysis (bottom) of γH2A.X (S139) and β-actin in Gl261 and CT2A GBM cell lines (N =
5). The protein expression was normalized to reference the protein β-actin expression.
Cell Survival
Cells were plated at 8,000 cells per well in a 96-well plate with 100
µl of medium per well, which were left overnight to equilibrate,
and assessed for confluency (%) after 72 h following the drug
treatments. Five images per 96 wells (×10 objective) were
acquired using the IncuCyte R© Live Imaging System (IncuCyte R©
Software (v2019B), Sartorius, Gottingen, Germany) and analyzed
using the imaging analysis software. Six wells were used per
treatment per experimental replicate.
Energy Metabolism Assays
Cells were plated at 40,000 cells per well in a 96-well plate
with 200 µl of medium per well and left overnight to
equilibrate. The Glycolysis (extracellular acidification; ab197244;
Abcam, Cambridge, UK), FAO Complete (ab222944; Abcam,
Cambridge, UK), and Extracellular Oxygen Consumption
(ab197243; Abcam, Cambridge, UK) assays were performed as
per the instructions of the manufacturer and detected using
the dual-read time-resolved fluorescence (FLUOstar Omega;
BMG LABTECH, Ortenberg, Germany). For FAO metabolism,
cells were glucose deprived overnight. Carbonyl cyanide 4-
(trifluoromethoxy) phenylhydrazone (FCCP; 2.5µm), etomoxir
(40µm), and antimycin A (1µm) were used as positive and
negative controls where appropriate. Data are expressed as
percentage effect of Lifetime (µs; Equation (1)) for the treatment
relative to the untreated control.






where, W1 and W2 are the times for the dual measurement
windows and D1 and D2 are the delay times prior to W1 and
W2, respectively.
Clonogenic/Colony Forming Unit Assay
Cells were seeded at 1,500 cells per well in 6-well plates with
2ml of DMEM/10% v/v FBS. After 10 days, colonies were
stained with crystal violet (0.5%w/v, 1:1methanol:distilled water)
and then imaged and quantitated using a vSpot R© Spectrum
ELISpot/FluoroSpot Reader System (Autoimmun Diagnostika
Gmbh, Straßberg, Germany). Three wells were used per
treatment per experimental replicate.
Functional Assays
Cells were plated at 500,000 cells per T25 flask, equilibrated
overnight, and then treated for 72 h. The Luminex R© Oxidative
Stress (ROS; Luminex Corp., Austin, TX, USA), DNA Damage
[ataxia telangiectasia mutated (ATM)/histone 2A family member
× (H2A.X)], Cell Cycle, Annexin-V, and Dead Cell, and
Autophagy LC3 assays were carried out according to the
instructions of the manufacturer. Cell events (1,000–5,000 assay
dependent) were acquired and analyzed using the Guava R©
Muse R© Cell Analyser (Luminex Corp., Austin, TX, USA).
Western Blot
About 50 µg protein was loaded on Any kDaTM Mini-
PROTEAN R© TGXTM Precast protein gels and transferred
to low-autofluorescence polyvinylidene fluoride (PVDF)
membranes (Bio-Rad, Hercules, CA, USA). For autophagy
Western blots, cells were treated with a 100 nM Bafilomycin
A1 (B1793; Sigma-Aldrich St. Louis, MO, USA) 4 h before
collection to accumulate LC3B in the cytoplasm. Primary
antibodies were γH2A.X (1:1,000; ab11174; Abcam, Cambridge,
UK), cyclin-dependent kinase 2 (Cdc2) (1:1,000; 28439S; Cell
Signaling Technology, Danvers, MA, USA), cyclin B1 (1:1,000;
4138S; Cell Signaling Technology, Danvers, MA, USA), p21
(1:1,000; ab188224; Abcam, Cambridge, UK), Bax (1:1,000;
ab3191; Abcam, Cambridge, UK), Bcl-2 (1:1,000; ab16904;
Abcam, Cambridge, UK), caspase 3 (1:1,000; ab188224; Abcam,
Cambridge, UK), SQSTM1/p62 (1:1,000; ab56416; Abcam,
Cambridge, UK), LC3B (1:1,000; PM036; MBL International
Corp., Woburn, MA, USA), and β-actin (1:10,000; A1978;
Sigma-Aldrich St. Louis, MO, USA). Immunoblots were detected
with 1:10,000 goat-anti-mouse DyLightTM 680 conjugated or
donkey-anti-rabbit DyLightTM 800 conjugated using an Odyssey
CLx Near-Infrared Fluorescence Imaging System (LI-COR
Biosciences, Lincoln, NE, USA).
In vivo Glioma Models
The murine survival study was reviewed, approved, and
performed in accordance with the guidelines of the Northern
Sydney Local Health District Animal Ethics Committee, Royal
North Shore Hospital, St Leonards, NSW, Australia (Approval
#RESP/17/205), which enforces the New South Wales Animal
Research Act 1985.
Eight-week-old male C57Bl/6 mice (20–26 g) were provided
by the Kearn’s Animal Facility, Australia. Mice were housed
in Allentown individually ventilated cages (3–5 per cage)
with cellulose bedding under specific pathogen-free conditions.
Enrichment was provided in the form of autoclaved ice block
sticks or straws. Rooms were temperature-controlled (22◦C)
and were kept on a 12-h light/dark cycle (7:00/19:00 h) with a
standard chow and water ad libitum.
Mice were inoculated with 1 × 105/2 µl murine glioma
Gl261 or CT2A cells using a stereotactic frame, a microinjection
unit (David Kopf Instruments, Tujunga, CA, USA), and a 5 µl
syringe with custom 32-G needle (Hamilton Company, Reno,
NV, USA) into the right caudoputamen (striatum) at 2mm in
mediolateral, 0.1mm in anteroposterior, 2.6mm in dorsoventral
bregma under isoflurane anesthesia (2% v/v per 1 L oxygen i.h.)
as described earlier (6). Mice were randomly assigned into one of
the eight treatment groups (six mice per group). Treatments were
administered five times a week for 2 weeks commencing at day 7
postinoculation: TMZ (50 mg/kg/day i.p.), DCA (200 mg/kg/day
i.p.), and Rano (50 mg/kg/day i.p.). External beam irradiation of
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FIGURE 6 | TMZ alone or combined with RT arrests Gl261 cells in the G2/M phase. (A) Representative Luminex® cell cycle histograms (Luminex Corp., Austin, TX,
USA) show fluorescent intensity as the G0/G1 phase in blue, the S phase in purple, and the G2/M phase in green. (B) Column graphs show mean ± SEM from three
independent experiments as in (A). ap < 0.05 vs. Unt; bp < 0.05 vs. TMZ; cp < 0.05 vs. RT; dp < 0.05 vs. DCA; ep < 0.05 vs. Rano; fp < 0.05 vs. DCA/Rano;
(Continued)
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FIGURE 6 | and gp < 0.05 vs. All-combined treatments were determined by the two-way ANOVA test along with the Tukey’s multiple comparison test. (C) Western
blot immunoblot (top) and densitometric analysis (bottom) of the expression of cyclin-dependent kinase 2 (cdc2), cyclin B1, p21, and β-actin in GBM cell lines
following treatment (N = 5). The protein expression was normalized to reference protein β-actin expression.
20Gy/10 (i.e., 2 Gy per dose; RT) was performed using the Image-
Guided SARRP (Xstrahl Inc., Suwanee, GA, USA) using a 5 ×
5mm collimator and 60◦ (30◦ to –30◦) Arc beam at a dose rate of
3.71 Gy/min (24). For combination treatment groups, radiation
was delivered 1-h post-drug administration.
Animal weight and well-being were assessed two times every
week and euthanized by cardiac puncture under isoflurane
anesthesia (2% v/v per 1 L oxygen i.h.) followed by cervical
dislocation at the humane endpoint or a long-term survival (100
days postinoculation). No adverse events were encountered.
Histopathological Analyses
Four-micron sections of paraffin-embedded tissues were stained
with Mayer’s H&E Y/erythrosine B staining, Ki67 (0.084µg/ml;
12202S; Cell Signaling Technologies, Danvers, MA, USA),
and γH2A.X (0.06µg/ml; ab11174; Abcam, Cambridge, UK)
as described earlier (6, 24) and terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) apoptosis by
immunohistochemical staining [ab206386; Abcam, Cambridge,
UK) with Mayer’s hematoxylin nuclear stain. Slides were imaged
using an Aperio XT slide scanner and captured using Aperio
ImageScope (Leica Biosystems, Wetzlar, Germany), and five
high-power images were assessed per sample (N = 4–6 brains
per treatment group] using ImmunoRatio (Seinajoki, Finland) as
described earlier (24).
Statistical Analyses
Drug IC50 concentrations were calculated using a four-
parameter response vs. drug concentration non-linear regression,
and synergistic doses were calculated using the CompuSyn
Software (Paramus, NJ, USA) (25, 26). To determine the
statistical difference between treatments, the two-way ANOVA
test along with the Tukey’s multiple comparison test were
performed for Annexin-V, DNA Damage, Oxidative Stress, and
Cell Cycle MUSE R© assays (Luminex Corp., Austin, TX, USA);
and the one-way ANOVA test was performed with the Dunn’s
multiple comparison test for Autophagy LC3, Western blot
fluorescent intensity, and CFU assays.Murine survival studies are
expressed as Kaplan–Meier curves. All statistics were performed
using the Prism version 8 for Windows (GraphPad Software Inc.,
San Diego, CA, USA), considering a significant p-value <0.05.
RESULTS
Glucose and FAO Metabolism in GBM
Using the publicly available HGCC gene expression dataset, we
investigated the glucose and FAO metabolic pathways in 48
GBM primary cell lines. Hierarchical clustering demonstrated
that glucose and FAO metabolic pathways did not differ
between the classical, mesenchymal, and proneural/neural
GBM subtypes, offering a potentially wide-ranging therapeutic
avenue (Figure 1A), compared to therapies targeting specific
genetic mutations (e.g., EGFR and IDH1). This contrasts a
recent report of 498 GBM IDH wildtype tumours which
demonstrated increased glycolytic activity in the mesenchymal
subtype (27).
Further examination showed that the expression of selected
targetable enzymes in the glycolytic pathway, pyruvate
dehydrogenase kinase (PDK) 1–4, and the FAO pathways,
acetyl CoA dehydrogenase (ACAD), thiolase [acetyl-coenzyme A
acetyltransferase (ACAT)], cronotase (ECH), and HADH, were
similarly expressed across the GBM subtypes, except ECH was
significantly higher in proneural/neural compared to classical
tumors (p= 0.0022; Figure 1B). To confirm the role of PDKs and
FAO enzymes in GBM, we compared the gene expression using
the TCGA GBM and normal brain. The expression of PDK1,
PDK3, ECH, and HADH were ∼1.5-fold higher in the GBM
tumors compared to the normal tissue (all p < 0.01; Figure 1C).
These data confirm that targetable metabolic pathways exist
within GBM.
From these results, we sought to investigate whether the
combination of PDK inhibitor, DCA, and FAO enzyme inhibitor,
Rano, can inhibit GBM cellular metabolism and cell growth and
can increase survival in the syngeneic Gl261 and CT2A models
of GBM.
Gl261 and CT2A Demonstrate Different
Sensitivities to Treatment
To determine the IC50 for drug and RT treatment, murine
GBM cell lines were treated with a 2-fold increase in drug
concentrations, and cell survival was assessed as either %
confluency at 72 h for drug treatment or colony-forming units
(CFUs) at 10 days for RT.
Gl261 was more TMZ-sensitive compared to CT2A (IC50;
2,526 vs. >10,000µM) but less sensitive to DCA (25.9 vs.
16.0mM), Rano (766.2 vs. 423.9µM), and RT (4.0 vs. 2.2Gy;
Figure 2A). Comparative IC50 for human immortalized GBM
cell lines U87-MG, U251-MG, and T98G is provided in
Supplementary Figure 1. Synergistic drug concentrations for
TMZ/RT and DCA/Rano were determined using the CompuSyn
Software (Paramus, NJ, USA) (25, 26). Combination indices
<1 indicate synergy, where 0 is additive and >1 antagonistic.
The combination indices indicated that the synergistic doses for
Gl261 were 39µM TMZ/2Gy RT and 37.5mM DCA/156µM
Rano and for CT2A were 19.5µM TMZ/1Gy RT and 37.5mM
DCA/39.06µM Rano (Figure 2B).
DCA and Rano Energy Metabolism Assays
Confirm Inhibition at Syngeneic Doses
To confirm that DCA and Rano synergistic drug doses were
sufficient to (partially) inhibit glycolytic and FAO metabolism,
respectively, we performed dual-read time-resolved fluorescent
assays. These assays measure the rate of fluorescent decay by
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FIGURE 7 | TMZ/RT and DCA/Rano induce autophagy in GBM cell lines. (A) Representative Luminex® histograms (Luminex Corp., Austin, TX, USA) of LC3
fluorescent intensity in Unt (blue) and treatment (red). (B) Column graphs show mean ± SEM from four independent experiments as in (A). ap < 0.05 vs. Unt; bp <
0.05 vs. TMZ; cp < 0.05 vs. DCA; dp < 0.05 vs. Rano; ep < 0.05 vs. TMZ/RT; and fp < 0.05 vs. All-combined treatments were determined by the Kruskal–Wallis test
(Continued)
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FIGURE 7 | along with the Dunn’s multiple comparison test. (C) Western blot immunoblot (top) and densitometric analysis (bottom) of the expression of p62, LC3-II,
and β-actin in GBM cell lines following treatment as indicated (N = 5). The protein expression was normalized to reference protein β-actin expression.
providing a more stable and greater dynamic range than the
traditional signal intensity measurements. Fluorescence lifetime
was calculated as described in “Energy Metabolism Assays”
section, and data were expressed relative to untreated controls
(Unt). Each drug decreased its respective metabolic pathway by
23–45% at 60min post-treatment (Figure 3A).
To assess the delayed impact on cell growth/survival, CFU
assays were performed (Figure 3B). Using the synergistic doses
identified in Figure 2B, DCA, Rano, and their combination
significantly reduced colony formation compared to Unt (all p
< 0.0001; Figure 3C), indicating no escape from the treatment
control or emergence of resistance. In contrast, TMZ and RT
alone and in combination with reduced CFU ∼50% showed
incomplete lethality. This suggests that DCA/Rano metabolic
targeting is a viable strategy that did not induce a resistant
population. We next sought to investigate potential chemo-
radio-enhancement in oxidative stress, DNA damage, cell cycle,
autophagy, and apoptotic mechanisms.
DCA/Rano Increases ROS Levels in Murine
GBM Cells
The ability of RT to induce DNA damage is dependent on the
generation of ROS (via radiolysis of water in cells). Inhibition
of glycolysis and FAO by DCA and Rano, respectively, should
increase the dependency of GBM cells on oxygen, thus increasing
the ROS levels. In both cell lines, DCA and DCA/Rano induced
an increase in ROS levels at 72-h post-treatment (Figure 4A).
However, this was not significantly greater than TMZ/RT
(Figure 4B). While all-combined treatments induced ROS
generation, DCA was the primary single-treatment contributor,
indicating that it may lead to increased DNA damage.
DCA and TMZ Increase DNA Damage in
Murine GBM Cells
To determine whether the increased ROS levels led to increased
DNA damage, phosphorylation of ATM (pATM) and H2A.X
(pH2A.X) were assessed as early indicators of DNA double-
strand breaks (DSB; Figure 5A). In both cell lines, DCA alone
and DCA/Rano significantly increased total DNA damage to
∼6-fold compared to Unt (p = 0.0059) and above that for
TMZ/RT (CT2A; p < 0.0001). In Gl261, this was reflected in
increased H2A.X phosphorylation and ATM activation (DNA
DSB) at 72 h, whereas CT2A cells showed predominantly
increased H2A.X phosphorylation (Figure 5B). Western blot of
γH2A.X protein expression confirmed upregulation at 72-h post-
treatment (Figure 5C).
DCA and Rano Do Not Significantly Alter
Cell Cycle Progression
The cell cycle contains several checkpoints to prevent the
proliferation of cells with DNA damage. To determine the
effect of DCA and Rano on cell cycle, the percentage of
cells in non/early-dividing (G0/G1), synthesis (S), and late-
dividing/mitosis (G2/M) were assessed (Figure 6A). Treatment
of Gl261 with TMZ or TMZ/RT led to an increase of 40% of
cells in the G2/M phase, whereas the same treatment in CT2A
had no effect (Figures 6A,B). This is consistent with an observed
reduction in the size of individual TMZ and RT-treated colonies
for Gl261 but not CT2A colonies in Figure 3B. TMZ/RT also
showed a trend toward upregulated Cdc2, which is necessary for
S/G2 and G2/M transition, but not cyclin B1 or p21 (Figure 6C).
However, in both cell lines, the DCA/Rano reduced G2/M
arrest, with a trend toward greater S-phase arrest, but did not
reach significance.
DCA and DCA/Rano Induce Autophagy in
GBM Cells Lines
DNA damage-induced autophagy can delay apoptotic cell death
by mediating the degradation of specific cell cycle proteins,
regulation of cell division, and promotion of DNA damage
repair. To determine whether DCA and Rano induce autophagy,
the expression of markers of the autophagosomal membrane,
microtubule-associated protein light chain 3-II (LC3), was
assessed by Luminex R© assay (Luminex Corp., Austin, TX, USA),
and Western blotting. In Gl261 cells, DCA/Rano, and all-
combined treatments induced the expression of LC3 (Figure 7A)
and 2.5-fold greater that LC3 induction of autophagy compared
to Unt (p < 0.0001) (Figure 7B). This was accompanied by a
decrease in the autophagy substrate p62 at 72-h post-treatment
(Figure 7C), though it did not reach significance. Similarly, in
CT2A cells, DCA, DCA/Rano, and all-combined treatments
showed a trend toward a 2-fold increase in LC3-autophagic
induction (p = 0.0211; Figure 7B). In CT2A cells, DCA, and
DCA/Rano showed increased p62 levels (Figure 7C). Although
p62 is recognized for its role in autophagic flux, it also has
roles in the anti-oxidative stress response, nutrient sensing, and
apoptosis (28), consistent with the increased ROS (Figure 4B)
and the Bax:Bcl-2 ratio (Figure 8C) noted in CT2A cells. These
results suggest that DCA induces autophagy in GBM cells but
may be more effective when combined with Rano in Gl261 cells,
as observed in the Gl261 DCA/Rano and all-combined groups.
DCA Alone or Combined Increases
Apoptosis in GBM Cell Lines
If GBM cells fail to overcome the increased ROS, DNA damage,
cell cycle arrest, and autophagy, they will finally undergo
apoptotic cell death. To assess the levels of apoptosis in Unt
Gl261 and CT2A, the membrane-impermeable DNA dye 7-
aminoactinomycin (7-AAD) and Annexin-V were assessed by
Luminex R© assay (Luminex Corp., Austin, TX, USA; Figure 8A).
In DCA, DCA/Rano, and all-combined treatments, the total
number of apoptotic cells increased 2- to 3-fold compared to Unt
(p= 0.0273; Figure 8B). In both cell lines, the total apoptosis was
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FIGURE 8 | DCA alone or in combination increases early apoptosis in GBM cell lines. (A) Representative Luminex® dot plots (Luminex Corp., Austin, TX, USA) show
live (lower left) annexin V(AV–)/7AAD(–) cells, early apoptotic (lower right) AV(+)/7AAD(–) cells, late apoptotic (upper right) AV(+)/7AAD(+) cells, and dead cells (upper
left) AV(–)/7AAD(+) cells. (B) Column graphs show mean ± SEM from three independent experiments as in (A). ap < 0.05 vs. Unt; bp < 0.05 vs. TMZ;
(Continued)
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FIGURE 8 | cp < 0.05 vs. RT; dp < 0.05 vs. DCA; ep < 0.05 vs. Rano; fp < 0.05 vs. DCA/Rano; and gp < 0.05 vs. All-combined treatments were determined by the
two-way ANOVA test along with the Tukey’s multiple comparison test. (C) Western blot immunoblot (top) and densitometric analysis (bottom) of the expression of Bax,
Bcl-2, caspase 3, and β-actin in GBM cell lines following treatment (N = 5). The protein expression was normalized to reference protein β-actin expression.
mostly manifested in increased early apoptotic events [annexin-
V+/7-AAD− (viability); Figure 8B]. Consistent with the CFU
data (Figure 3B), TMZ/RT did not significantly induce apoptosis
(Figure 8B). To assess the nature of the apoptotic signal, we
determined the expression of early proapoptotic protein Bax and
anti-apoptotic protein Bcl-2 and late apoptotic cleaved caspase 3
(Figure 3C) by immunoblotting. In both cell lines, the Bax:Bcl-2
ratio, and caspase 3 in CT2Awere increased byDCA,DCA/Rano,
and all-combined treatments (Figure 8C), suggesting that DCA
induces the mitochondrial (intrinsic) apoptotic pathway in GBM
cell lines. In CT2A cells, TMZ, and TMZ/RT increased caspase 3
in the absence of increased annexin V and Bax:Bcl-2 (Figure 8C).
For explanation, see “Discussion” section.
DCA/Rano Increases in vivo Murine GBM
Survival
Our in vitro data shows that DCA induces ROS generation,
DNA damage, autophagy, and apoptosis, whereas, the effects of
Rano were minimal. Some of the effects of Rano treatment have
been shown to affect the immune and tumor microenvironment
and the function of normal astrocytes and neurons (12, 13).
To determine the clinical effect of Rano and combination
treatments, we use two orthotopic syngeneic murine models
(Supplementary Figure 2). Mice were injected intracranially
with 1 × 105/2 µl Gl261 or CT2A cells on day 0 and TMZ (50
mg/kg/day i.p.), DCA (200 mg/kg/day i.p.), Rano (50 mg/kg/day
i.p.), and/or RT (20 Gy/10) treatment were administered daily
from day 7 to 18. For both Gl261 and CT2A tumor models,
DCA, Rano, and DCA/Rano significantly increased survival;
up to 20% in Gl261 tumor-bearing mice (median survival; 21
vs. 17.5 days; p < 0.0001) and 40% in CT2A tumor-bearing
mice compared to Unt tumor-bearing controls (29.5 vs. 21 days;
p < 0.0001; Figure 9A). No significant differences in toxicity
(as assessed by weight of animals) between treatments were
observed (data not shown). Consistent with our in vitro IC50
data (Figure 2A), the median survival for CT2A tumor-bearing
mice demonstrated greater TMZ resistance and RT sensitivity
than Gl261 tumor-bearing mice (Figure 9A). The TMZ/RT
combination in both models was superior to DCA/Rano with
50% median survival, thus not reaching the 100-day period
(indicating long-term survival).
The histopathological analysis of the tumor morphology
revealed that DCA and DCA/Rano induced focal regions of
necrosis and hemorrhage with increased Ki67 proliferation
indices and DNA fragmentation (cell death; TUNEL staining) in
Gl261 tumors (Figure 9B); Rano significantly decreased Ki67 in
Gl261 tumors but increased TUNEL in CT2A tumors. Tumors
treated with TMZ and/or RT and all-combined treatment
showed increased DNA damage (γH2A.X; p< 0.001; Figure 9C).
We have previously observed this phenomenon of prolonged
γH2A.X at 28 days after RT treatment in noncancerous
brain, lung, and colon tissues (24). As the patterning is
not observed in unirradiated (untreated) brains, we believe
that it indicates radiotoxicity to the “healthy” cells, including
radiosensitive oligodendrocytes, which have shown limited
regenerative capacity out to 18-month postirradiations (29). In
brain tissue where tumors resolved, TUNEL staining was limited
to immune cells present along the wound tract (Figure 9B) and
therein not quantitated.
DISCUSSION
Contrary to a recent report by Duraj and colleagues (27), we
show that glucose and FAO metabolic pathways are similar
among GBM subtypes, and enzymes of the glycolytic and FAO
pathways are upregulated in GBM tumors compared to normal
brain tissues. While many therapies aim to target the genetic
differences in GBM tumors (e.g., EGFR, IDH, FGFR, and TACC),
the inhibition of GBM cellular energetics is a potentially wide
ranging approach with impact irrespective of GBM subtype.
Chemoradiation forms part of the “standard of care” for
patients with GBMs; therefore, we compared the effects of DCA,
Rano, and DCA/Rano in relation to chemoradiation and their
known mechanism of action; ROS > DNA damage > cell cycle
> apoptosis/autophagy, as well as in vivo efficacy. DCA and
Rano induced oxidative stress, DNA damage, autophagy, and
apoptosis (summarized in Supplementary Figure 3). At 72 h,
the CT2A cells had lower ROS levels and less ATM activation
compared to Gl261 cells. The subtle disparity in the response
of Gl261 and CT2A cells may be partially attributable to
differences in TP53 with Gl261 (P53MUT) and CT2A (P53WT)
(30). TP53 is one of the most commonly dysregulated genes
in GBM, with up to 54% of patients with TP53MUT depending
on the GBM subtype (1). However, it is reported that P53WT
inhibits lipid synthesis and glycolysis in normal and tumor cells,
whereas T53MUT promotes lipid synthesis and glycolysis (31). In
tumor cells, it is not that simple. Not all P53 mutants increase
glycolysis (32) and wild-type P53 can promote the metabolic
switch from oxidative phosphorylation to glycolysis by inducing
p53 upregulated modulator of apoptosis (PUMA)-mediated
disruption of mitochondrial pyruvate uptake in cancer cells (33).
Therein where we would have expected Gl261 (P53MUT) to be
more sensitive to DCA, we instead observed higher IC50s for
both DCA and Rano in the Gl261 line due to its precedence. In
normal cells, wild-type P53 positively regulates ferroptosis, yet
in tumor cells, TP53MUT sensitizes tumor cells to ferroptosis, a
process noted to have a role in TMZ resistance and is associated
with GBM autophagy and apoptotic mechanisms (31). Further,
examination of the P53 mutant and wild-type regulation of
glycolytic and FAO pathways in GBM is needed.
One point of difference in our study was that in both cell lines,
DCA increased annexin V, Bax:Bcl-2 ratio, and CT2A caspase
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FIGURE 9 | DCA and Rano increased median survival but were not more efficacious than chemoradiation. Mice were injected intracranially with 1 × 105/2 µl murine
GBM cells on day 0 and TMZ (50 mg/kg/day i.p.), DCA (200 mg/kg/day i.p.), Rano; 50 mg/kg/day i.p.), and/or RT (20 Gy/10) treatment administered daily from day 7
to day 21. (A) The Kaplan–Meier plots show median survival per treatment and are indicated in the graph legend. Six mice per treatment were monitored for 100-day
(Continued)
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FIGURE 9 | postinoculation or until humane endpoint. (B) Endpoint Gl261 (top) and CT2A (bottom) tumors were immunohistochemically stained for cell proliferation
marker, Ki67, DNA damage marker, γH2A.X (S139), and apoptotic marker, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) stain. (C) Column
graphs of the quantitation of positively stained cells in treated mice compared to controls. Data are expressed as mean ± SEM for five high-power fields (N = 6
tumors per treatment group). ap < 0.05 vs. Unt; bp < 0.05 vs. TMZ; cp < 0.05 vs. RT; dp < 0.05 vs. DCA; ep < 0.05 vs. Rano; fp < 0.05 vs. TMZ/RT; gp < 0.05 vs.
DCA/Rano; and hp < 0.05 vs. All-combined treatments were determined by the two-way ANOVA test along with the Tukey’s multiple comparison test. n.d., not
determined.
3, indicating that DCA induces the mitochondrial (intrinsic)
apoptotic pathway in GBM cell lines. Yet, in CT2A, but not
Gl261 cells, TMZ increased caspase 3 without increased annexin
V or Bax:Bcl-2. A study by Roos et al. (34) proposed that, in
glioma cells, O6-methylating agents, such as TMZ, induce the
accumulation of DNA DSBs. In P53WT cells (e.g., CT2A), this
induction activates the extrinsic apoptotic pathway via FasR
and caspase 8, whereas in P53MUT cells (e.g., Gl261) the same
response triggers the intrinsic apoptotic pathway via Bax:Bcl-2
and caspase 9. Both apoptotic pathways led to increased caspase
3 cleavage. Therein in our study, DCA and TMZ may trigger the
intrinsic and extrinsic apoptotic pathways in CT2A, respectively,
which was not observed in Gl261 cells due to differences in P53
status; however, we cannot account for the absence of membrane
translocation for TMZ-treated CT2A cells in this study.
In line with other murine models examining glycolytic
inhibitors, 2-DG, and/or FAO inhibitors, etomoxir or Rano, in
GBM, lung and colon cancers, median survival, or tumor growth
were minimally affected (11, 13). However, the combination
strategy showed an enhanced antitumor effect (13). The observed
20–40% increase in median survival in syngeneic murine
models using DCA/Rano (Gl261: 17.5 vs. 21 days, p < 0.0001
and CT2A: 21 vs. 28 days, p < 0.0001) was comparable to
an immunocompromised model of GBM (MES93) using 2-
DG/etomoxir, which increased median survival from 17 to 24
days (p < 0.001) (11). It is noted that the effects of Rano on
the cell may not be limited to FAO inhibition. Although, noted
as a partial FAO inhibitor, Rano was found to lack the FAO-
interfering activity in complete media with or without serum
(35), despite showing FAO-inhibiting ability in our FAO assay
utilizing glucose-deprivation and a single FAO source (18C
unsaturated fatty acid oleate).
In GBM, DCA has shown promising results across a range
of preclinical studies, yet these data have not translated into
pronounced improvements in the few clinic trials undertaken
thus far. Although, we demonstrated in vitro that DCA and Rano
induced ROS, DNA damage, autophagy, and apoptosis, our in
vivo survival data did not reflect this. In vivo dose, regimen, and
sequencing of drugs may have limited therapeutic efficacy. In
the present study, we administered DCA and Rano concurrently
with chemoradiation. As most DNA damage from RT is due
to indirect ionization of oxygen and increased ROS (peaking
at ∼30–120min post-RT) and FDA clinical pharmacokinetic
data available for TMZ, DCA, and Rano indicating that they
reach peak plasma concentrations (Cmax) at 1–2 h, we elected
to deliver RT at ∼1-h post-drug administration. This contrasts
phase I clinical trials in recurrent GBM, wherein, patients
received DCA monotherapy two times daily for 30 days, without
chemoradiation (36), and Rano monotherapy is FDA approved
for administration two times daily for the treatment of angina.
Further, elucidation of the best dose regimen and sequencing
of the novel or repurposed therapeutics to target cancer cell
metabolism will improve efficacy.
In GBM, the peripheral neuropathy of the patient from DCA
has been noted, albeit transient and dose-dependent (15). The
computational modeling reveals that the docking binding energy
values of DCA are PDK2 > PDK1 > PDK4 > PDK3 (37),
suggesting that DCA has greatest binding affinity for PDK2,
for which we showed no significant difference in PDK2 gene
expression between GBM tumors and normal brain tissue in
the TCGA dataset. Of equal concern is the fact that in vitro
concentrations of DCA are in the millimolar range, raising the
notion that DCA derivatives, novel or repurposed drugs with
selective PDK1/3 binding affinity, and micromolar or nanomolar
IC50s may be better therapeutic avenues to explore.
In conclusion, the present study shows that dual glycolytic and
FAO targeting with and without concomitant chemoradiation
warrants further investigation in immunocompetent syngeneic
models for GBM.
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Supplementary Figure 1 | Sensitivity and survival of murine and human glioma
cell lines to drug and RT treatment combinations. Drug IC50s for TMZ, DCA, and
Rano were determined from confluency (%) at 72 h, and RT by clonogenic assay
at 10-day post-treatment using the four-parameter logistic model. Symbols show
mean survival (%) ± SEM for six replicates per experiment (N = 3). U-87MG did
not form colonies in the RT assessment.
Supplementary Figure 2 | Experimental timeline for Gl261 and CT2A
tumor-bearing mice. Drugs and radiation therapy (RT) were assessed individually
and in combination; RT 2 Gy/10, 50 mg/kg i.p. TMZ, 200 mg/kg i.p. DCA, and/or
50 mg/kg i.p. Rano five times per week for 2 weeks commencing at day 7
post-intracranial injection of 1 × 105/2 µl Gl261 or CT2A cells. Mice were
euthanized at humane endpoints or at day 100 postinoculation (considered
long-term survival).
Supplementary Figure 3 | Schematic representation of DCA and Rano inhibition
on murine GBM cell lines. Drugs and chemoradiation were assessed individually
and in combination. PS, phosphatidylserine.
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